SBIR/STTR Research Award
Novel Adjuvant to Enhance Immunity Against PIV3
Award amount
$50,000Program and phase
SBIR · Phase IAward year
1993Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Secretech, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
We will apply a novel adjuvant to the production of an effective, safe vaccine against PIV3. The proposed adjuvant is a proprietary formulation of microcrystalline cellulose, starch, and sugar. We will use a hamster model to test the ability of the novel adjuvant to enhance the immune response to PIV3. Octylglucoside soluble envelope proteins of PIV3 will be used as the vaccine antigen. The efficacy of the vaccine preparation will be tested by analyzing serum and bronchial samples from immunized animals in virus specific ELISA and virus neutralization studies to determine the magnitude and type of the immune response and by determining titers of virus in the lung after challenge with live virus. In subsequent studies, the efficacy of the adjuvant used in combination with subunit PIV3 vaccines and recombinant parainfluenza vaccine will be explored.
Technology keywords
Not reported